Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men
| dc.contributor.author | Bremner, William J. | en_US |
| dc.contributor.author | Bagatell, Carrie J. | en_US |
| dc.contributor.author | Rivier, Jean E. | en_US |
| dc.date.accessioned | 2008-10-17T20:40:55Z | |
| dc.date.available | 2008-10-17T20:40:55Z | |
| dc.date.issued | 1995-07 | en_US |
| dc.description.abstract | OBJECTIVE: To test the hypothesis that over a 4-week treatment period, Nal-Glu GnRH antagonist ([AcD2Nal1, D4ClPhe2, D3Pal3, Arg5, DGlu6 [AA], DAla10] GnRH) at a dose of 200 micrograms/kg per day SC would suppress levels of immunologically active and biologically active LH and FSH more completely than a dose of 100 micrograms/kg per day. DESIGN: Placebo controlled clinical study. SETTING: A university community. SUBJECTS: Thirty normal male volunteers. INTERVENTIONS: We administered Nal-Glu at doses of 0, 100, and 200 micrograms/kg body weight per day in combination with T enanthate, 50 mg IM weekly, to separate groups of men (9 or 10 men per group) for 4 weeks. RESULTS: Serum levels of immunologically active and biologically active gonadotropins were suppressed similarly in both groups of men who received Nal-Glu; this suppression was significantly greater than in the men who received placebo + T. Local side effects were more severe in the Nal-Glu 200 micrograms/kg per day group. CONCLUSIONS: Administration of Nal-Glu in combination with T suppresses gonadotropins more completely than does T alone, but at doses > 100 micrograms/kg, gonadotropins are not suppressed additionally with larger doses of Nal-Glu. Subjects experienced greater local discomfort and side effects with the higher dosage. These findings suggest that dosages of Nal-Glu of > 100 micrograms/kg per day may have no advantage over the 100-micrograms/kg dose in a male contraceptive regimen. | en_US |
| dc.identifier.citation | Fertil Steril. 1995 Jul;64(1):139-45 | en_US |
| dc.identifier.uri | http://hdl.handle.net/1773/4327 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | gonadotropins | en_US |
| dc.subject | male contraception | en_US |
| dc.subject | GnRH antagonist | en_US |
| dc.subject | testosterone | en_US |
| dc.subject | gonadotropin-releasing hormone | en_US |
| dc.subject.mesh | Male | en_US |
| dc.subject.mesh | Luteinizing Hormone, blood | en_US |
| dc.subject.mesh | Research Support, Non-U.S. Gov't | en_US |
| dc.subject.mesh | Research Support, U.S. Gov't, P.H.S. | en_US |
| dc.subject.mesh | Radioimmunoassay | en_US |
| dc.subject.mesh | Adult | en_US |
| dc.subject.mesh | Fluoroimmunoassay | en_US |
| dc.subject.mesh | Testosterone, analogs & derivatives, blood, pharmacology | en_US |
| dc.subject.mesh | Biological Assay | en_US |
| dc.subject.mesh | Research Support, U.S. Gov't, Non-P.H.S. | en_US |
| dc.subject.mesh | Gonadotropins, blood | en_US |
| dc.subject.mesh | Humans | en_US |
| dc.subject.mesh | Gonadorelin, adverse effects, analogs & derivatives, antagonists & inhibitors, pharmacology | en_US |
| dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
| dc.subject.mesh | Drug Synergism | en_US |
| dc.title | Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men | en_US |
| dc.type | Article | en_US |
